1. Can the pharmaceutical industry reduce attrition rates?;Kola;Nat Rev Drug Discov,2004
2. Innovation/stagnation: challenge and opportunity on the critical path to new medical products March 2004 http:www.fda.govScienceResearchSpecialTopicsCriticalPathInitiativeCriticalPathOpportunitiesReportsucm077262.htm
3. End-of-phase 2a meetings. FDA guidance for Industry September 2009 http:www.fda.govdownloadsDrugsGuidanceComplianceRegulatoryInformationGuidancesucm079690.pdf
4. Claret L Girard P Zuideveld KP et al A longitudinal model for tumor size measurements in clinical oncology studies PAGE 15 2006 http:www.page-meeting.orgabstract1004
5. Model-based prediction of phase III overall survival in colorectal cancer based on phase II tumor dynamics;Claret;J Clin Oncol,2009